The target audience for this activity is hematologists and oncologists who treat patients with MM. Physicians, nurses, and other health care professionals interested in the treatment of MM are also invited to participate.
Almost all patients with multiple myeloma (MM) eventually relapse with the disease course typically involving multiple relapses and remissions. Therapy selection for relapsed or refractory (R/R) MM is nuanced and affected by many variables. This along with the availability of novel therapies and accumulating evidence can make it difficult for clinicians to select appropriate therapy for individual patients. This accredited program discusses patient cases, applicable data, and management strategies in order to facilitate care for patients across the MM disease continuum.
Upon successful completion of this activity, you should be better prepared to: